Epidermal growth factor receptor (EGFR) exon 20 insertion and atypical mutants (EGFR exon 20ins/atypical)

The Epidermal growth factor receptor (EGFR) exon 20 insertion and atypical mutants represent a specific class of oncogenic alterations primarily found in non-small cell lung cancer (NSCLC) (Vyse & Huang, 2019). Unlike common sensitizing mutations such as exon 19 deletions, these variants are characterized by structural changes in the kinase domain that reduce the binding affinity of early-generation tyrosine kinase inhibitors (TKIs) (Robichaux et al., 2018). Exon 20 insertions specifically result in a "pushed" C-helix conformation, which narrows the ATP-binding pocket and leads to constitutive, ligand-independent signaling (Remon et al., 2020). Atypical mutants, including G719X, L861Q, and S768I, also drive tumor growth but show varying degrees of sensitivity to different therapeutic agents compared to classical mutations (Harrison et al., 2020). These mutations activate downstream pathways such as MAPK/ERK and PI3K/Akt, which are essential for cell proliferation and survival (Signal Transduction and Targeted Therapy, 2019). Therapeutic intervention has shifted toward next-generation TKIs like mobocertinib and sunvozertinib, as well as bispecific antibodies like amivantamab that target the extracellular domain (FDA, 2021). Amivantamab works by blocking ligand binding and promoting receptor degradation, bypassing the pocket-size constraints of small molecules (Journal of Clinical Oncology, 2021). Clinical management is often complicated by the narrow therapeutic window, as these drugs frequently inhibit wild-type EGFR in healthy tissues, causing significant dermatological and gastrointestinal toxicities (Nature Reviews Clinical Oncology, 2020). Identification of these specific mutations through next-generation sequencing is critical for selecting the appropriate targeted therapy (PubMed, 2022). Overall, this target group represents a significant challenge in precision oncology due to its heterogeneous response to treatment and the necessity for mutation-specific inhibitors.

Other names

EGFR exon 20 insertionUncommon EGFR mutationsAtypical EGFR mutationsERBB1 exon 20insHER1 atypical mutantsEGFR exon 20ins

Inhibition of the intracellular tyrosine kinase domain or extracellular ligand binding to prevent downstream oncogenic signaling.